Veradermics is trading lower in early trading on October 20; available reporting does not identify a specific catalyst.

  • Shares are at $116.35, down -4.85%.
  • Veradermics rose 12.37% on October 19 after positive Phase 3 Study 304 results for VDPHL01 met primary and secondary endpoints in 536 men.
  • The Nasdaq is down 0.84%, while biotech is up 2.09%; neither offers a clear same-direction explanation.